Literature DB >> 2701927

Strategies and perspectives in treatment of respiratory infections.

H J Neijens1.   

Abstract

Bronchopulmonary infections in CF have a number of special features. The pathophysiology is determined by consequences of the basic CF defect and interactions with host defence systems, leading to chronic inflammation induced by Staphylococci and subsequently Pseudomonas. This results in lung tissue damage, various complications and eventually respiratory insufficiency. Policy of treatment is to combat infectious exacerbations and lung tissue destruction as much as possible. Factors in optimal treatment such as strategies, indications for therapy and selection of antibiotics are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2701927     DOI: 10.1111/apa.1989.78.s363.66

Source DB:  PubMed          Journal:  Acta Paediatr Scand Suppl        ISSN: 0300-8843


  3 in total

1.  Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients.

Authors:  P Vic; S Ategbo; D Turck; M O Husson; E Tassin; G A Loeuille; A Deschildre; D Druon; J C Elian; C Arrouet-Lagandre; J P Farriaux
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

2.  Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.

Authors:  P Vic; S Ategbo; D Turck; M O Husson; V Launay; G A Loeuille; A Sardet; A Deschildre; D Druon; C Arrouet-Lagande
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

3.  Adult cystic fibrosis: association of acute pulmonary exacerbations and increasing severity of lung disease with auxotrophic mutants of Pseudomonas aeruginosa.

Authors:  R F Taylor; M E Hodson; T L Pitt
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.